Climb Bio, Inc. quarterly report, Q1 FY2023

Business context and reporting period

The supplied filing is Eliem Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, filed May 11, 2023. This does not match the request metadata naming Climb Bio, Inc.; verify the issuer before relying on this summary. Eliem is a pre-revenue biotechnology company developing therapies for neuronal excitability disorders. It paused ETX-155 development and is focusing resources on its preclinical Kv7.2/3 program, led by ETX-123.

Financial results and liquidity

Cash, cash equivalents and short-term marketable securities totaled $109.4 million at March 31, 2023, down from $123.6 million at December 31, 2022. Cash and cash equivalents alone were $34.4 million. Current assets were $120.2 million and current liabilities $4.9 million. Total liabilities were $5.2 million, primarily lease liabilities; the filing reports no debt balance. No operating margin is meaningful because the company has no revenue and incurred an operating loss. Accumulated deficit was $143.2 million.

Investing activities provided $5.8 million net, mainly reflecting maturities of marketable securities exceeding purchases. Financing activities provided $1,000 from option exercises. Stock-based compensation was $10.2 million, including significant restructuring-related expense.

Material changes versus the prior comparable period

• Net loss increased by $9.1 million year over year, while operating expenses increased 78.5%.
• R&D expense fell as clinical and preclinical costs declined, principally following ETX-810’s discontinuation in August 2022; lower U.K. R&D tax credits partly offset the cost reduction.
• G&A expense rose sharply, largely due to $14.0 million of restructuring costs recorded in that function.
• Operating cash use increased by $4.4 million year over year.

Outlook, management commentary, risks and unusual items

• The February 2023 restructuring followed the decision to pause ETX-155 and prioritize the preclinical Kv7.2/3 program. The workforce reduction was approximately 55%. Q1 restructuring costs were $15.8 million; expected aggregate costs were approximately $16.6 million, with actions expected to be substantially complete by Q3 2023.
• Management’s MD&A estimates existing cash, cash equivalents and marketable securities can fund operations into 2027. The liquidity note separately says the resources are sufficient for at least the next 12 months from the filing date. These statements differ in specificity; runway depends on assumptions and may be shorter.
• ETX-123 IND-enabling studies were underway, with Phase 1 studies planned for the first half of 2024. These are plans, not assured milestones. The filing says ETX-155’s IND had FDA clearance for a potential Phase 2 MDD trial, but further development was paused; a future trial could be conducted by Eliem or a strategic partner.
• The company expects continuing losses and substantial additional funding needs. It may seek equity or debt financing, collaborations, licensing and U.K. R&D tax credits; financing may be unavailable or dilutive, and could require program delays or reductions.
• Two material weaknesses in internal control over financial reporting remained, and disclosure controls were deemed ineffective as of March 31, 2023. Management described remediation efforts but had not concluded they were fully effective.
• Key risks include early-stage drug-development and safety uncertainty, dependence on ETX-123, third-party research and manufacturing, funding needs, and the possibility that U.K. tax-credit eligibility or benefits change. The filing identifies no material legal proceedings and no off-balance-sheet arrangements.

Important facts for investors to verify

1. Confirm the filing issuer: the supplied document is for Eliem Therapeutics, Inc., not Climb Bio, Inc.
2. Reconcile the stated cash runway—“into 2027” in MD&A versus “at least the next twelve months” in the liquidity note—and review the assumptions behind it.
3. Track ETX-123 IND-enabling progress and whether the planned first-half 2024 Phase 1 start remains feasible.
4. Confirm restructuring completion, final costs and any effects on staffing or development timelines.
5. Monitor remediation and testing of the disclosed internal-control material weaknesses.
6. Assess future financing needs, U.K. tax-credit receipts and potential dilution or partnership terms.